ロード中...
Pegylated Interferon for the Adjuvant Treatment of Melanoma: FDA Approved, but What Is Its Role?
The article by Herndon and colleagues on the approval of peginterferon-alfa-2b for the adjuvant treatment of patients with resected node-positive melanoma, published in this issue of The Oncologist, is examined, and the relevance of this therapy in clinical practice discussed.
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3481887/ https://ncbi.nlm.nih.gov/pubmed/23002125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0368 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|